Two level III studies showed contradictory evidence in advanced NSCLC and metastatic pancreatic cancer patients where overexpression of ERCC1 showed benefit from platinum based chemotherapy [22, 23]. This evidence concerns the gene ERCC1 and non-small cell lung carcinoma.